282 related articles for article (PubMed ID: 28543818)
1. Bone Formation Is Coupled to Resorption Via Suppression of Sclerostin Expression by Osteoclasts.
Koide M; Kobayashi Y; Yamashita T; Uehara S; Nakamura M; Hiraoka BY; Ozaki Y; Iimura T; Yasuda H; Takahashi N; Udagawa N
J Bone Miner Res; 2017 Oct; 32(10):2074-2086. PubMed ID: 28543818
[TBL] [Abstract][Full Text] [Related]
2. Treatment of OPG-deficient mice with WP9QY, a RANKL-binding peptide, recovers alveolar bone loss by suppressing osteoclastogenesis and enhancing osteoblastogenesis.
Ozaki Y; Koide M; Furuya Y; Ninomiya T; Yasuda H; Nakamura M; Kobayashi Y; Takahashi N; Yoshinari N; Udagawa N
PLoS One; 2017; 12(9):e0184904. PubMed ID: 28937990
[TBL] [Abstract][Full Text] [Related]
3. Lrp4 in osteoblasts suppresses bone formation and promotes osteoclastogenesis and bone resorption.
Xiong L; Jung JU; Wu H; Xia WF; Pan JX; Shen C; Mei L; Xiong WC
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3487-92. PubMed ID: 25733894
[TBL] [Abstract][Full Text] [Related]
4. Sclerostin expression in trabecular bone is downregulated by osteoclasts.
Koide M; Yamashita T; Murakami K; Uehara S; Nakamura K; Nakamura M; Matsushita M; Ara T; Yasuda H; Penninger JM; Takahashi N; Udagawa N; Kobayashi Y
Sci Rep; 2020 Aug; 10(1):13751. PubMed ID: 32792620
[TBL] [Abstract][Full Text] [Related]
5. Scl-Ab reverts pro-osteoclastogenic signalling and resorption in estrogen deficient osteocytes.
Allison H; Holdsworth G; McNamara LM
BMC Mol Cell Biol; 2020 Nov; 21(1):78. PubMed ID: 33148174
[TBL] [Abstract][Full Text] [Related]
6. SOST gene suppression stimulates osteocyte Wnt/β-catenin signaling to prevent bone resorption and attenuates particle-induced osteolysis.
Jiao Z; Chai H; Wang S; Sun C; Huang Q; Xu W
J Mol Med (Berl); 2023 May; 101(5):607-620. PubMed ID: 37121919
[TBL] [Abstract][Full Text] [Related]
7. Rictor is required for optimal bone accrual in response to anti-sclerostin therapy in the mouse.
Sun W; Shi Y; Lee WC; Lee SY; Long F
Bone; 2016 Apr; 85():1-8. PubMed ID: 26780446
[TBL] [Abstract][Full Text] [Related]
8. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
Peng S; Liu XS; Huang S; Li Z; Pan H; Zhen W; Luk KD; Guo XE; Lu WW
Bone; 2011 Dec; 49(6):1290-8. PubMed ID: 21925296
[TBL] [Abstract][Full Text] [Related]
9. Osteocyte-Related Cytokines Regulate Osteoclast Formation and Bone Resorption.
Kitaura H; Marahleh A; Ohori F; Noguchi T; Shen WR; Qi J; Nara Y; Pramusita A; Kinjo R; Mizoguchi I
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708317
[TBL] [Abstract][Full Text] [Related]
10. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.
Michael H; Härkönen PL; Väänänen HK; Hentunen TA
J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275
[TBL] [Abstract][Full Text] [Related]
11. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
[TBL] [Abstract][Full Text] [Related]
12. Activation of mTORC1 in B Lymphocytes Promotes Osteoclast Formation via Regulation of β-Catenin and RANKL/OPG.
Xu S; Zhang Y; Liu B; Li K; Huang B; Yan B; Zhang Z; Liang K; Jia C; Lin J; Zeng C; Cai D; Jin D; Jiang Y; Bai X
J Bone Miner Res; 2016 Jul; 31(7):1320-33. PubMed ID: 26825871
[TBL] [Abstract][Full Text] [Related]
13. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
14. Regulatory mechanisms of sclerostin expression during bone remodeling.
Koide M; Kobayashi Y
J Bone Miner Metab; 2019 Jan; 37(1):9-17. PubMed ID: 30357564
[TBL] [Abstract][Full Text] [Related]
15. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
16. Osteoprotegerin deficiency attenuates strontium-mediated inhibition of osteoclastogenesis and bone resorption.
Peng S; Liu XS; Zhou G; Li Z; Luk KD; Guo XE; Lu WW
J Bone Miner Res; 2011 Jun; 26(6):1272-82. PubMed ID: 21611968
[TBL] [Abstract][Full Text] [Related]
17. Osteocyte control of bone remodeling: is sclerostin a key molecular coordinator of the balanced bone resorption-formation cycles?
Sapir-Koren R; Livshits G
Osteoporos Int; 2014 Dec; 25(12):2685-700. PubMed ID: 25030653
[TBL] [Abstract][Full Text] [Related]
18. PTH (1-34) affects bone turnover governed by osteocytes exposed to fluoride.
Yu X; Yu H; Jiang N; Zhang X; Zhang M; Xu H
Toxicol Lett; 2018 May; 288():25-34. PubMed ID: 29447955
[TBL] [Abstract][Full Text] [Related]
19. Resorption controls bone anabolism driven by parathyroid hormone (PTH) receptor signaling in osteocytes.
Rhee Y; Lee EY; Lezcano V; Ronda AC; Condon KW; Allen MR; Plotkin LI; Bellido T
J Biol Chem; 2013 Oct; 288(41):29809-20. PubMed ID: 23963454
[TBL] [Abstract][Full Text] [Related]
20. Sclerostin vaccination mitigates estrogen deficiency induction of bone mass loss and microstructure deterioration.
Wang FS; Wu RW; Lain WS; Tsai TC; Chen YS; Sun YC; Ke HJ; Li JC; Hwang J; Ko JY
Bone; 2018 Jul; 112():24-34. PubMed ID: 29653294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
